1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
China Medicine Corp.

China Medicine Corp.

CHME
China Medicine Corp.US flagOther OTC
0.02
USD
- -
- -
486,097.00Market Cap
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
TTM
Revenue per Share
1.43
2.29
3.26
3.41
3.54
4.24
2.46
Basic EPS, GAAP
0.41
0.87
0.65
0.56
0.6
0.11
0.23
Free Cash Flow per Basic Share
0.35
0.15
-0.41
-0.22
0.1
0.87
0.24
Dividend per Share
0.32
- -
- -
- -
- -
- -
- -
Book Value per Share
0.17
0.58
1.09
1.13
1.46
1.5
0.93
Tangible Book Value per Share
0.25
0.73
1.91
2.48
2.79
1.89
2.29
Basic Weighted Avg Shares
7
7
7
12
15
15
27
Sales/Revenue/Turnover
10
15
24
42
54
65
66
Operating Margin (%)
23.25
35.37
25.78
19.98
20.37
18.94
17.8
Depreciation Expense
- -
- -
- -
1
- -
1
2
Net Income, GAAP
3
6
5
7
9
2
6
Effective Tax Rate (%)
- -
- -
20.55
19.56
18.22
71.68
39.67
Profit Margin (%)
28.27
38.12
19.96
16.33
17.01
2.65
9.17
Working Capital
2
4
13
29
33
16
86
LT Debt
- -
- -
- -
- -
- -
- -
- -
Total Equity
2
5
14
32
44
46
78
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
225.38
81.19
62.53
50.48
7.63
23.72

Capital Structure

FRC

•

in mil. unless spec.
Mar'10
Jun'10
Sep'10
ST Debt
11
5
3
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
20
23
24
Market Capitalization
57
45
55

Working Capital

FRC

•

in mil. unless spec.
Mar'10
Jun'10
Sep'10
Total Current Assets
102
99
94
Cash, Cash Equivalents & STI
11
9
8
Accounts Receivable, Net
22
25
17
Inventories
4
4
6
Total Current Liabilities
18
12
8
Payables & Accruals
6
6
4
ST Debt
11
5
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
98.38%
4.37%
Free Cash Flow
- -
25.9%
761%
Net Income, GAAP
- -
14.57%
-81.18%
Sales/Revenue/Turnover
- -
45.57%
20.7%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
7
12
11
24
54
2009
10
15
19
20
65
2010
11
17
18
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
0.08
0.16
0.13
- -
0.6
2009
0.04
- -
0.21
- -
0.11
2010
0.1
0.19
0.06
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
- -
- -
- -
- -
- -
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Senshan Yang
Full Time Employees
281
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Address
2/F, Guangri Tower Guangzhou GD People's Republic of China 510006
IPO Date
Nov 30, 2006
Website
cmc621.com
Similar Companies
Dechra Pharmaceuticals PLC (DCHPF)
Entia Biosciences, Inc. (ERGO)
Sastasundar Ventures Limited (SASTASUNDR.NS)
Alibaba Health Information Technology Limited (ALBBY)
Cosmo N.V. (0RGI.L)
Sibannac, Inc. (SNNC)
Business
China Medicine Corporation China Medicine Corporation (CHME) engages in the development, manufacture, and distribution of western pharmaceuticals, traditional Chinese medicines, and healthcare products in the People's Republic of China. The company offers prescription and over-the-counter drugs, including Shuangdan Capsules for cardiodynia treatment, Houerhuan Anti-inflammatory Capsules, Shugan Yipi Granules, Danggui Tiaojing Granules, Huangzao Granules, Pingfeng Shengmai Capsules, Danqi Tablets, and Naodesheng Tablets; dietary supplements such as BeThin Tablets, Refrelizer Herbal Tea, LifeFull Herbal Tea, and Relaxetox Herbal Tea; chinese herbs; nutritional supplements; medical devices; and medical formulations. China Medicine Corporation operates primarily through its wholly-owned subsidiary Guangzhou Konzern Medicine Co., Ltd., targeting hospitals, pharmacies, and consumers across China with a focus on oncology, hypertension, and toxin removal applications. Founded in 2005 and headquartered at 2/F, Guangri Tower, No. 9 Siyounan Road 1st Street, Guangzhou, Guangdong Province, the company--originally Lounsberry Holdings III, Inc.--maintains a network for over 2,000 pharmaceutical and related products while pursuing proprietary research and development, including patented production protocols registered with China's State Food and Drug Administration. Recent financials reflect trailing twelve-month revenue of $65.76 million and net income of -$113,320 as of mid-2025, with the firm reporting no sales activity in recent quarterly filings amid a microcap market capitalization under $30,000; historical initiatives include a 2010 $69.6 million equity financing agreement with One Equity Partners for expansion following the LifeTech Pharmaceuticals acquisition and earlier pursuits of vertical integration via manufacturing acquisitions in Guangzhou.